PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
Sophie Park(Centre Hospitalier Universitaire de Grenoble), Didier Bouscary(Université Paris Cité), Zachary A. Knight(Howard Hughes Medical Institute), Patrick Mayeux(Université Paris Cité), Nabih Azar(Assistance Publique – Hôpitaux de Paris), Norbert Ifrah(Institut National du Cancer), Nathalie Gallay(Inserm), Nicolas Chapuis(Délégation Paris 5), Valérie Bardet(Délégation Paris 5), Kevan M. Shokat(Howard Hughes Medical Institute), F Viguié(Délégation Paris 5), François Dreyfus(Université Paris-Sud), Jérôme Tamburini(Centre National de la Recherche Scientifique), C. Lacombe(Délégation Paris 5), Lise Willems(Hôpital Cochin)
Cited by 193
Related Papers
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
|Nature|2013|2.5k
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
|Nature|2010|1.8k
IRE1 Signaling Affects Cell Fate During the Unfolded Protein Response
|Science|2007|1.4k
The translational landscape of mTOR signalling steers cancer initiation and metastasis
|Nature|2012|1.4k
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k